Search Within

Stephen D Nimer

  1. "David Straus"
Formats
  1. Journal Article (8)
  2. Meeting Abstract (6)
Groups
  1. Center for Hematologic Malignancies (14)
  2. Department of Medicine (14)
  3. Hematologic Malignancies, Division of (14)
  4. Lymphoma (14)
  5. Radiation Oncology, Department of (11)
  6. Survivorship Research (11)

More Groups

People
  1. Andrew Zelenetz (14)
  2. Carol Portlock (14)
  3. Craig Moskowitz (14)
  4. David Straus (14)
  5. Ariela Noy (11)
  6. Joachim Yahalom (11)

More People

Years
  1. 2012 (1)
  2. 2010 (1)
  3. 2008 (1)
  4. 2007 (1)
  5. 2005 (1)
  6. 2004 (1)

More Years

Publications
  1. Blood (10)
  2. Annals of Oncology (1)
  3. Bone Marrow Transplantation (1)
  4. British Journal of Haematology (1)
  5. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (10)
  2. American Society of Clinical Oncology (1)
  3. John Wiley & Sons (1)
  4. Nature Publishing Group (1)
  5. Oxford University Press (1)

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Journal Article

    Moskowitz, C. H.; Matasar, M. J.; Zelenetz, A. D.; Nimer, S. D.; Gerecitano, J.; Hamlin, P.; Horwitz, S.; Moskowitz, A. J.; Noy, A.; Palomba, L.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging: Research paper
    Journal Article

    Moskowitz, C. H.; Yahalom, J.; Zelenetz, A. D.; Zhang, Z.; Filippa, D.; Teruya-Feldstein, J.; Kewalramani, T.; Moskowitz, A. J.; Rice, R.; Maragulia, J.; more...
    British Journal of Haematology (2010)

    Fulltext@MSK | Save
  • Normalization of FDG-PET pre-ASCT with additional non-cross resistant chemotherapy improves EFS in patients with relapsed and primary refractory Hodgkin lymphoma - Memorial Sloan Kettering protocol 04-047
    Meeting Abstract

    Moskowitz, C. H.; Nimer, S. D.; Zelenetz, A. D.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; Portlock, C. S.; Straus, D. J.; Gerecitano, J.; Kewalramani, T.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
    Journal Article

    Moskowitz, C. H.; Hamlin, P. A.; Gabrilove, J.; Bertino, J. R.; Portlock, C. S.; Straus, D. J.; Gencarelli, A. N.; Nimer, S. D.; Zelenetz, A. D.
    Annals of Oncology (2007)

    Fulltext@MSK | Save
  • Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-Cell lymphomas: Minimal benefit when analyzed by intent to treat
    Meeting Abstract

    Horwitz, S.; Moskowitz, C.; Kewalramani, T.; Hamlin, P.; Straus, D.; O'connor, O.; Noy, A.; Portlock, C.; Nimer, S.; Palomba, M. L.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
    Journal Article

    Kewalramani, T.; Zelenetz, A. D.; Nimer, S. D.; Portlock, C.; Straus, D.; Noy, A.; O'connor, O.; Filippa, D. A.; Teruya-Feldstein, J.; Gencarelli, A.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • Risk-adpated high dose chemoradiotherapy and ASCT for patients with relapsed and primary refractory Hodgkin's disease: An intent to treat analysis
    Meeting Abstract

    Moskowitz, C. H.; Kewalramani, T.; Nimer, S. D.; Rice, R. D.; Rosenzweig, L.; Horwitz, S.; Noy, A.; O'connor, O.; Portlock, C. S.; Straus, D.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
    Journal Article

    Hamlin, P. A.; Zelenetz, A. D.; Kewalramani, T.; Qin, J.; Satagopan, J. M.; Verbel, D.; Noy, A.; Portlock, C. S.; Straus, D. J.; Yahalom, J.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • An analysis of accelerated full course chemotherapy followed by upfront high dose therapy (HDT) and autologous stem cell transplantation (ASCT) for patients with International Prognostic Index IV (IPI IV) aggressive NHL
    Meeting Abstract

    Moskowitz, C. H.; Kewalramani, T.; Donnelly, G.; Zelenetz, A. D.; Noy, A.; Rice, D.; Kuznetsov, M.; Straus, D.; Nimer, S. D.; Portlock, C. S.
    Blood (2002)

    Fulltext@MSK | Save
  • Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)
    Meeting Abstract

    Kewalramani, T.; Zelenetz, A.; Bertino, J.; Donnelly, G.; Hedrick, E.; Noy, A.; O'connor, O.; Portlock, C.; Straus, D.; Yahalom, J.; more...
    Blood (2001)

    Fulltext@MSK | Save